Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBITDA: 2013-2024

Historic EBITDA for Soleno Therapeutics (SLNO) over the last 9 years, with Dec 2024 value amounting to -$175.5 million.

  • Soleno Therapeutics' EBITDA fell 183.62% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 17.49%. This contributed to the annual value of -$175.5 million for FY2024, which is 350.11% down from last year.
  • Latest data reveals that Soleno Therapeutics reported EBITDA of -$175.5 million as of FY2024, which was down 350.11% from -$39.0 million recorded in FY2023.
  • In the past 5 years, Soleno Therapeutics' EBITDA ranged from a high of -$24.1 million in FY2022 and a low of -$175.5 million during FY2024.
  • For the 3-year period, Soleno Therapeutics' EBITDA averaged around -$79.5 million, with its median value being -$39.0 million (2023).
  • Data for Soleno Therapeutics' EBITDA shows a maximum YoY plummeted of 350.11% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Soleno Therapeutics' EBITDA stood at -$24.1 million in 2022, then tumbled by 62.00% to -$39.0 million in 2023, then tumbled by 350.11% to -$175.5 million in 2024.